Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.535 USD | +3.65% |
|
-2.90% | -25.34% |
Feb. 10 | Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer | CI |
Nov. 26 | Iovance Biotherapeutics Names Raj Puri as Chief Regulatory Officer | MT |
Capitalization | 1.63B 1.56B 1.47B 1.3B 2.31B 141B 2.58B 17.53B 6.5B 58.76B 6.1B 5.98B 249B | P/E ratio 2024 * |
-4.23x | P/E ratio 2025 * | -5.99x |
---|---|---|---|---|---|
Enterprise value | 1.38B 1.33B 1.25B 1.1B 1.97B 120B 2.2B 14.91B 5.53B 49.98B 5.19B 5.09B 212B | EV / Sales 2024 * |
8.52x | EV / Sales 2025 * | 3.36x |
Free-Float |
90.74% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Iovance Biotherapeutics, Inc.
1 day | +3.46% | ||
1 week | -1.05% | ||
Current month | -3.76% | ||
1 month | -4.41% | ||
3 months | -34.46% | ||
6 months | -44.31% | ||
Current year | -23.92% |







Director | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 51 | 2021-06-17 |
Director of Finance/CFO | 52 | 2020-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 2021-06-30 |
Manager | Title | Age | Since |
---|---|---|---|
Ryan Maynard
BRD | Director/Board Member | 55 | 2015-02-15 |
Director/Board Member | 57 | 2016-06-06 | |
Iain Dukes
CHM | Chairman | 66 | 2016-08-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 0 M€ | -6.03% | - | |
0.93% | 1 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.11% | 0 M€ | -.--% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+3.46% | -1.05% | -41.05% | -66.35% | 1.63B | ||
+0.16% | -5.11% | -18.19% | -35.15% | 9.36B | ||
+3.88% | -1.24% | +60.77% | +39.66% | 3.07B | ||
-0.60% | +9.91% | +13.38% | -41.03% | 2.67B | ||
+0.74% | +11.31% | +200.90% | -40.56% | 1.33B | ||
-0.06% | +7.72% | +114.34% | -42.43% | 1.26B | ||
+1.10% | -5.75% | -10.53% | -56.12% | 731M | ||
+1.58% | -9.06% | -19.13% | -86.05% | 584M | ||
+3.91% | +7.13% | +124.28% | +193.19% | 276M | ||
+0.32% | -3.52% | +1.61% | - | 211M | ||
Average | +1.44% | -2.61% | +42.64% | -14.98% | 2.11B | |
Weighted average by Cap. | +1.00% | -4.29% | +19.53% | -27.28% |
2024 * | 2025 * | |
---|---|---|
Net sales | 163M 156M 147M 130M 231M 14.09B 258M 1.75B 649M 5.87B 609M 597M 24.85B | 455M 436M 412M 363M 647M 39.45B 722M 4.9B 1.82B 16.43B 1.71B 1.67B 69.58B |
Net income | -362M -347M -328M -289M -515M -31.42B -575M -3.9B -1.45B -13.08B -1.36B -1.33B -55.42B | -260M -249M -235M -207M -370M -22.55B -413M -2.8B -1.04B -9.39B -975M -955M -39.77B |
Net Debt | -243M -233M -220M -194M -345M -21.07B -386M -2.62B -971M -8.77B -911M -893M -37.16B | -100M -96.14M -90.81M -80.08M -143M -8.71B -159M -1.08B -401M -3.62B -376M -369M -15.36B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 5.525 $ | +3.46% | 6,042,132 |
25-02-13 | 5.340 $ | 0.00% | 7,753,648 |
25-02-12 | 5.340 $ | +0.95% | 5,625,417 |
25-02-11 | 5.290 $ | -0.56% | 9,467,979 |
25-02-10 | 5.320 $ | -6.50% | 11,176,645 |
Delayed Quote Nasdaq, February 14, 2025 at 11:39 am EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IOVA Stock